Top Insider Buys: • Viridian Therapeutics, Inc. (NASDAQ:VRDN) saw Mahoney make a substantial investment in • Viridian Therapeutics, Inc.'s stock.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Fintel
85.71%
investing.com
14.29%
•
•
•
•
•
•
•
•
Country
US
Industry
Health Care
Market Cap
Small Cap
Num. Employees
60
IPO Date
Jun 11, 2021
Country
US
Industry
Health Care
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 60 full-time employees. The company went IPO on 2021-06-11. Its initial focus is on developing a class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. The company is developing a pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr. PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. Its TRACIr program targets PD-L1xCD28.
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data
Related Stocks
Related Stocks
Stocks being mentioned with JANX